BMS Announces Operational Restructuring with Q3 Financials

Oct 27, 2016

In addition to announcing positive third quarter results this week, Bristol-Myers Squibb Company also revealed plans for a restructuring of the company’s operating model.

The restructuring is designed to help BMS focus resources behind the its highest priorities, accelerate its pipeline and simplify infrastructure.

Specifically, according to BMS, the new model will involve a "more focused investment in commercial opportunities against key brands and markets, a competitive and more agile R&D organization that can accelerate the pipeline, streamlined operations and realigned manufacturing capabilities that broaden biologics capabilities to reflect current and future portfolio."

Read the BMS press release